Cadre Holdings, Inc. (CDRE) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $6.5M sold). 1 member of Congress reported 1 purchase vs 0 sales. Latest close $31.88 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Aug 25, 2026 · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold CDRE. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 4 sales ($6.5M). Insider trading 1 member of Congress reported buying (1 purchase vs 0 sales). Latest buy: Jun 30, 2026. Politician trading
INTUITIVE SURGICAL INC (ISRG) · ZIMMER BIOMET HOLDINGS, INC. (ZBH) · Edwards Lifesciences Corp (EW) · ESTABLISHMENT LABS HOLDINGS INC. (ESTA) · MSA Safety Inc (MSA) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.01% | 306,458 | NEW Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +13.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 155 of 8,857 filers |
| Long-only filers among them | 155 |
| Change vs 2026 Q1 | -7 net · 151 entered · 158 exited |
| Shares reported, all filers | 32,964,184 |
| Reported value, all filers | $895.1M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842) |
| Revenue · FY2025 | $610.3M |
| Net income · FY2025 | $44.1M |
| Total assets · FY2025 | $770.0M |
| Shares outstanding | 42,820,734 |
| Market cap (at latest close) | $1.4B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 1,886,616 |
| Share of shares outstanding | 4.41% |
| Days to cover | 3.21 |
Shares short at recent settlements — Jul 31, 2026: 3.1M · Aug 14, 2026: 2.3M · Aug 31, 2026: 2.2M · Sep 15, 2026: 2.3M · Sep 30, 2026: 2.0M · Oct 15, 2026: 1.9M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 24 · Aug 14, 2026: 0 · Aug 31, 2026: 3K · Sep 15, 2026: 0 · Sep 30, 2026: 2K · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 4 sales by 1 insider ($6.5M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | KANDERS WARREN B | CEO AND CHAIRMAN | Sell | 55,345 | $31.54 | $1.7M | SEC filing |
| Aug 25, 2026 | KANDERS WARREN B | CEO AND CHAIRMAN | Sell | 44,655 | $32.28 | $1.4M | SEC filing |
| Aug 24, 2026 | KANDERS WARREN B | CEO AND CHAIRMAN | Sell | 65,431 | $33.20 | $2.2M | SEC filing |
| Aug 24, 2026 | KANDERS WARREN B | CEO AND CHAIRMAN | Sell | 34,569 | $33.65 | $1.2M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | Warren B. Kanders | Officer, Director | 100,000 | $3.2M | Aug 25, 2026 | SEC filing |
| Aug 24, 2026 | Warren B. Kanders | Officer, Director | 100,000 | $3.3M | Aug 24, 2026 | SEC filing |
| Aug 17, 2026 | Brad Williams | Officer | 88,742 | $3.0M | Aug 17, 2026 | SEC filing |
| Jun 15, 2026 | Warren B. Kanders | Officer, Director | 300,000 | $9.3M | Jun 15, 2026 | SEC filing |
| Mar 20, 2026 | Warren B Kanders | Officer, Director | 200,000 | $6.3M | Mar 20, 2026 | SEC filing |
| Dec 12, 2025 | Blaine Browers | Officer | 20,435 | $899.1K | Dec 12, 2025 | SEC filing |
| Dec 10, 2025 | Brad Williams | Officer | 24,000 | $1.0M | Dec 10, 2025 | SEC filing |
| Nov 17, 2025 | Warren B. Kanders | Officer, Director | 1,343,941 | $56.6M | Nov 17, 2025 | SEC filing |
| Nov 13, 2025 | Brad Williams | Officer | 27,370 | $1.2M | Nov 13, 2025 | SEC filing |
| Oct 24, 2025 | Williams Brad | Officer | 4,132 | $177.7K | Oct 24, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Sep 30, 2026 | SCHEDULE 13D/A | +29.6% (close Oct 1, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Oct 1, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Warren B. Kanders | SC 13D/A | 11,117,928 | 25.8% | Sep 28, 2026 | SEC filing |
| Aug 6, 2026 | FMR LLC | SC 13G/A | 2,475,622.54 | 5.8% | Jun 30, 2026 | SEC filing |
| Jun 18, 2026 | Warren B. Kanders | SC 13D/A | 11,392,928 | 26.4% | Jun 16, 2026 | SEC filing |
| May 14, 2026 | Capital International Investors | SC 13G/A | 1,260,806 | 3.0% | Mar 31, 2026 | SEC filing |
| May 6, 2026 | FMR LLC | SC 13G/A | 3,319,196.11 | 7.8% | Mar 31, 2026 | SEC filing |
| Feb 12, 2026 | REINHART PARTNERS, LLC. | SC 13G | 2,170,349 | 5.3% | Dec 31, 2025 | SEC filing |
| Feb 5, 2026 | FMR LLC | SC 13G/A | 3,798,654.83 | 9.3% | Dec 31, 2025 | SEC filing |
| Nov 19, 2025 | Warren B. Kanders | SC 13D/A | 11,692,570 | 27.7% | Nov 17, 2025 | SEC filing |
| Nov 14, 2025 | Warren B. Kanders | SC 13D | 13,036,511 | 30.9% | Nov 10, 2025 | SEC filing |
| Aug 12, 2025 | Warren B. Kanders | SC 13G/A | 11,823,511 | 28.9% | Jun 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (1 purchase vs 0 sales). Bought by Democrats. Latest buy: Jun 30, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Cisneros, Gilbert | House | D | 1 | 0 | Jun 30, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).
Federal contracts: $3.0M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $2.2M |
| FY2022 | $543.0K |
| FY2023 | $0 |
| FY2024 | $45.8K |
| FY2025 | $0 |
| FY2026 | $169.7K |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Key figures
· Growth — Latest revenue: $610.3M · 5-yr revenue CAGR: 8.6% · Straight growth years: 5
· Graham — Current ratio: 3.50 · Straight profitable years: 6 · Debt ratio: 1.42 · Latest net income: $44.1M
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.41 · Operating cash flow: $63.7M · Net income: $44.1M
· Bought by Members — Members buying: 1 · Buy txns: 1 · Sell txns: 0 · Latest buy: Jun 30, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold CDRE — ranked by lift, the co-holding pattern described in Methodology: INTUITIVE SURGICAL INC (ISRG) · ZIMMER BIOMET HOLDINGS, INC. (ZBH) · Edwards Lifesciences Corp (EW) · ESTABLISHMENT LABS HOLDINGS INC. (ESTA) · MSA Safety Inc (MSA) · STERIS plc (STE) · ALIGN TECHNOLOGY INC (ALGN) · Enovis CORP (ENOV).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 16, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
| Nov 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 7, 2026 · 8-K/A | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
INTUITIVE SURGICAL INC (ISRG) · Track Record: how the signals scored · Practice timing on CDRE
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.